Theresa Hunter Gibble, PhD, MPH, MS (she/her/hers)

Director
Eli Lilly and Company

Poster(s):

• (3.08) Tirzepatide Improved Health-Related Quality of Life in Adults with Obesity or Overweight: Results from the SURMOUNT-3 phase 3 trial
  Thursday, May 9, 2024

  11:05 AM – 11:20 AM CDT

• (3.09) Improvements in Physical Functioning Among Participants With Obesity With Limitations in Physical Function at Baseline: Results from SURMOUNT-1 and SURMOUNT-2 Trials
  Thursday, May 9, 2024

  11:05 AM – 11:20 AM CDT

• (3.10) Tirzepatide Improves Health-Related Quality of Life in Participants With Obesity or Overweight and Type 2 Diabetes: Results From Phase 3 SURMOUNT-2 Trial
  Thursday, May 9, 2024

  11:05 AM – 11:20 AM CDT